REGN - Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) insider Andrew Murphy sold 4,147 shares of the stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at
What happened Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 shares on 10/14/2026. The shares sold for $753.76 to $781.47 each and brought in about $3.20 million, according to the Form 4. The filing says the trades were made under a Rule 10b5-1 trading plan. The same filing shows
Regeneron's revenue is growing at a good clip despite declining Eylea sales. Dupixent is the main reason behind recent strong financial results.
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment
First Citizens Bank and Trust Co. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,281 shares of the biopharmaceutical company's stock, valued at approximately $1,730,000. Other
Hotter-than-expected inflation sent stocks and crypto tumbling Wednesday, and Wall Street analysts wasted no time reshuffling their targets on Thursday, with major calls hitting Bank of America, Netflix, PayPal, and several energy giants all at once.
Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. In the first part of the year before we invested, Abbott slightly missed earnings estimates while it was digesting its acquisition of Exact Sciences, along with a variety of turmoil in the medtech and infant nutrition industries. Digital and print publisher People Inc. was a detractor in the quarter, while hospitality and entertainment company MGM Resorts also detracted.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The market is regaining confidence in Avantor's ability to grow organically and in Emmanuel Ligner's turnaround plan. Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. Building products company Fortune Brands Innovations saw its stock price decline in Q3, retracing Q2's positive move related to excitement over Jesse Singh's appointment as CEO.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
NorthCrest Asset Manangement LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 7.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,712 shares of the biopharmaceutical company's stock after acquiring an additional 749 shares during the
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Monday shared encouraging 84-week findings from the Phase 3 OPTIMA trial for its drug Pasatru (garetosmab-grts).
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP Late-breaking data presented at ASBMR show sustained efficacy of Pasatru and a consistent safety profile from weeks 56 to 84, supporting long-term disease control TARRYTOWN, N.Y., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru™ (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP).
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What happened Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said on October 1, 2026, it entered the Sixth Amendment with Sanofi. Under the amendment, Sanofi will make a $1.0 billion upfront payment. The companies also agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies that target IL-13, IL-4, IL-4R and IL-4xIL-13. Global profits on sales of
Central Pacific Bank Trust Division raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 90.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,687 shares of the biopharmaceutical company's stock after purchasing an additional 1,275 shares during the period.
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Thursday shared clinical trial results for two investigational therapies targeting recurrent ovarian cancer and muscle loss prevention during weight management.
SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.